RCMI Coordinating Center (RCMI CC) Header Logo

Connection

George Perry to Luteinizing Hormone

This is a "connection" page, showing publications George Perry has written about Luteinizing Hormone.
Connection Strength

0.505
  1. Webber KM, Casadesus G, Bowen RL, Perry G, Smith MA. Evidence for the role of luteinizing hormone in Alzheimer disease. Endocr Metab Immune Disord Drug Targets. 2007 Dec; 7(4):300-3.
    View in: PubMed
    Score: 0.077
  2. Webber KM, Perry G, Smith MA, Casadesus G. The contribution of luteinizing hormone to Alzheimer disease pathogenesis. Clin Med Res. 2007 Oct; 5(3):177-83.
    View in: PubMed
    Score: 0.076
  3. Casadesus G, Milliken EL, Webber KM, Bowen RL, Lei Z, Rao CV, Perry G, Keri RA, Smith MA. Increases in luteinizing hormone are associated with declines in cognitive performance. Mol Cell Endocrinol. 2007 Apr 15; 269(1-2):107-11.
    View in: PubMed
    Score: 0.073
  4. Webber KM, Casadesus G, Perry G, Atwood CS, Bowen R, Smith MA. Gender differences in Alzheimer disease: the role of luteinizing hormone in disease pathogenesis. Alzheimer Dis Assoc Disord. 2005 Apr-Jun; 19(2):95-9.
    View in: PubMed
    Score: 0.064
  5. Bowen RL, Verdile G, Liu T, Parlow AF, Perry G, Smith MA, Martins RN, Atwood CS. Luteinizing hormone, a reproductive regulator that modulates the processing of amyloid-beta precursor protein and amyloid-beta deposition. J Biol Chem. 2004 May 07; 279(19):20539-45.
    View in: PubMed
    Score: 0.059
  6. Bowen RL, Smith MA, Harris PL, Kubat Z, Martins RN, Castellani RJ, Perry G, Atwood CS. Elevated luteinizing hormone expression colocalizes with neurons vulnerable to Alzheimer's disease pathology. J Neurosci Res. 2002 Nov 01; 70(3):514-8.
    View in: PubMed
    Score: 0.054
  7. Bowen RL, Perry G, Xiong C, Smith MA, Atwood CS. A clinical study of lupron depot in the treatment of women with Alzheimer's disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks. J Alzheimers Dis. 2015; 44(2):549-60.
    View in: PubMed
    Score: 0.032
  8. Bonda DJ, Lee HP, Lee HG, Friedlich AL, Perry G, Zhu X, Smith MA. Novel therapeutics for Alzheimer's disease: an update. Curr Opin Drug Discov Devel. 2010 Mar; 13(2):235-46.
    View in: PubMed
    Score: 0.023
  9. Webber KM, Casadesus G, Marlatt MW, Perry G, Hamlin CR, Atwood CS, Bowen RL, Smith MA. Estrogen bows to a new master: the role of gonadotropins in Alzheimer pathogenesis. Ann N Y Acad Sci. 2005 Jun; 1052:201-9.
    View in: PubMed
    Score: 0.016
  10. Casadesus G, Atwood CS, Zhu X, Hartzler AW, Webber KM, Perry G, Bowen RL, Smith MA. Evidence for the role of gonadotropin hormones in the development of Alzheimer disease. Cell Mol Life Sci. 2005 Feb; 62(3):293-8.
    View in: PubMed
    Score: 0.016
  11. Casadesus G, Zhu X, Atwood CS, Webber KM, Perry G, Bowen RL, Smith MA. Beyond estrogen: targeting gonadotropin hormones in the treatment of Alzheimer's disease. Curr Drug Targets CNS Neurol Disord. 2004 Aug; 3(4):281-5.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support